The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.
Of the 27 companies in the index, 12 firms' share prices retreated last month, 14 companies' stocks increased, and one firm's share value was flat.
The firm's molecular diagnostics revenue increased nearly 11 percent with global sales of $170.9 million.
The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.
Product and service revenues were up 10 percent year over year to $22.4 million compared to $20.4 million in the year-ago quarter.
The company also reported higher operating costs as it worked to develop and validate its Parsortix circulating tumor cell collection system for clinical use.
John McDonough announced he is moving into an executive chairman role and will step down as CEO. The firm has begun searching for a new CEO.
For the three months ended June 30, the genomic testing firm reported total revenues of $30.1 million.
Qiagen's Q2 revenues of $381.6 million represented 5 percent year-over-year growth at constant exchange rates, but came in just under the Wall Street estimate.
The company attributed the revenue increase to strong performance by its Primerdesign molecular diagnostics and Lab21 protein diagnostics units.